Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine

DeVorkin L, et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 2022

‍

This poster describes a large panel of fully human CD3-binding antibodies discovered using integrated antibody discovery, characterization, and engineering technologies. Antibody binding assessments show key species cross-reactivity and binding epitopes distinct from commonly used parental antibodies, including SP34–2. In a second discovery campaign designed to enhance the number of cross-reactive antibodies, hundreds of additional unique antibody sequences were identified. Finally, in proof-of-concept experiments, the OrthoMab™ bispecifics platform was used to generate potent EGFR x CD3 T-cell engagers that maintain low levels of cytokine production.

‍‍